Last Updated on December 31, 2023 by The Health Master
The Pharmacy Council of India (PCI) has issued a clarification stating that the decisions of its Central Council and various Executive Committees reducing the intake in various pharmacy courses are to be read with the Council’s notification on October 22, which restored the approved admission intake of the previous year to the years 2022–23.
The clarification is to remove any confusion that may remain among the stakeholders regarding the admission intake to the pharmacy institutions during the years 2022–23, as opposed to the approved admission intakes during the previous academic year.
The circular says:
“Decisions of Central Council and various Executive Committees reducing the intake in various pharmacy courses are to be read with the Council’s notification dated October 22, 2022, notifying that whenever admission intake was reduced in the 2022–23 academic session in pharmacy course(s), the previously approved intake during the 2021–22 academic session is restored for the 2022–23 academic session also,” said the latest clarifying circular issued by the PCI.
In an Executive Committee meeting held on October 15, 2022, the Council decided that wherever admission intake was reduced in the 2022–23 academic session in pharmacy courses, the previously approved intake during the 2021–22 academic session be restored for the 2022–23 academic session also.
It has also decided to notify all such institutes that an affidavit should be uploaded on the institution’s dashboard on the portal of PCI, New Delhi, within one month of receipt of the notification, without fail.
PCI notification says:
“There should not be any change/modification/alteration to the affidavit provided with this notification.”
“In case any change is observed, the same will not be entertained at any cost, and the liabilities will rest only with the Institute and not PCI.”
In view of this, all institutions are directed to submit the prescribed affidavit along with their appeal application and update the faculty data on the PCI portal within one month of receipt of the notification.
The information to be submitted include the increase in intake, which is applicable in case the institution has applied earlier at the time of submission of the Standard Inspection Format (SIF) for the year 2022-23; introduction of new courses such as D Pharm, B Pharm, M Pharm, Pharm D, Pharm D (PB) and B Pharm (practice); and restoration of reduced seats.
Affidavit to be submitted by the Institutions
The institutes need to submit the affidavit on a Rs 100 nonjudicial stamp paper in case approval is granted or the admissions are restored for the years 2022–23; the same is subject to verification of the compliance report by the PCI at any later date.
In case compliance is found to be false, unsatisfactory, fraudulent/misleading, the principal or head of the institution, the Department Secretary of the state government in the case of government institutions, or those who are signatories to the affidavit will be liable for action as per the law of the country.
The format of the affidavit says:
“PCI may initiate action as deemed fit, including notice under Section 13(1) of the Pharmacy Act, 1948, for withdrawal of approval and the consequences thereof; the responsibility will rest with the institution itself, and PCI shall not be held responsible for this,”
The PCI had earlier prescribed a format for the appeal process for the institutions if the decisions of approval for the academic session 2022–23 communicated by the Council were not satisfactory.
Pharmacy-practice-amend-Regulation-2021
PCI-dt-23-06-2021-Draft-Syllabus-for-Diploma-Course-in-Pharmacy
The-Education-Regulations-2020-for-Diploma-Course-in-Pharmacy-09-10-2020
PCI-Notification-dt-16-07-2019-Pharma-D-Automatically-Eligible-For-Posts-Meant-For-Bpharma-D-Pharma
Pharmacy-Practice-Regulations-2015
Bachelor-of-Pharmacy-Practice-Regulations-2014
Drug recall: These drugs recalled by Aurobindo for this reason
Lab-made Blood given to people in world-first Clinical Trial
USFDA gives tentative approval for Drospirenone tablets
IPC adds 10 new Impurity Reference Substances to IP 2022
USFDA issues warning letter to Lupin API plant
NPPA to consider Retail Price Fixation of this Asthma Drug Combination
USFDA approves Ketorolac Tromethamine injection
300 Drug Formulations to have mandatory Bar Codes
USFDA gives final approval for Sodium Phenylbutyrate tablets
IPC clarifies on uniformity of dosage units & impurities in IP 2022
Latest Notifications regarding Pharmaceuticals
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
